02:51 PM EDT, 09/11/2025 (MT Newswires) -- Absci ( ABSI ) said Thursday it is working with Oracle's (ORCL) Cloud Infrastructure and AMD (AMD) to advance generative AI-driven drug discovery through its generative AI drug creation platform.

The company said it selected Oracle Cloud Infrastructure to support the development of AI models and scaling of its AI workflows, including simulations and antibody design.

The collaboration also integrates AMD's latest MI355X GPUs to enhance performance and scalability, it said.

Shares of Absci ( ABSI ) were up over 15% in recent trading.

Price: 2.75, Change: +0.37, Percent Change: +15.55